Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Biomarker Improves Head and Neck Cancer Patient Prognosis

By Labmedica International staff writers
Posted on 31 Jan 2012
A molecular fingerprint in head and neck cancers can predict whether a patient's tumor will be life threatening.

The molecular fingerprint biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This biomarker could become a component of a new test to guide how aggressively those with head and neck tumors should be treated.

A study was performed at Albert Einstein College of Medicine of Yeshiva University (Bronx, NY, USA) and Montefiore Medical Center (Bronx, NY, USA), the University Hospital for Einstein. Tissue samples were taken from tumors and nearby healthy tissue of 123 head and neck cancer patients at Montefiore and levels of 736 microRNAs were measured. Of all the microRNAs measured, one in particular–miR-375– stood out for being the most down-regulated in head and neck tumors compared with its levels in adjacent normal tissue.

The 123 patients were ranked according to how extreme the difference was between the miR-375 in their tumor and in adjacent normal tissue, with that difference expressed as the ratio: miR-375 level in patient's tumor tissue divided by miR-375 level in patient's normal tissue. All patients were then followed throughout the course of their illness.

MiR-375 proved to be a highly useful biomarker for predicting disease outcome. The patients for whom the difference between their tumor and normal-tissue miR-375 levels was most extreme (i.e., the one-fourth of patients with the lowest ratios) were nearly 13 times more likely to die or 9 times more likely to experience distant spread (metastasis) of their cancer compared to patients with higher miR-375 ratios.

The findings were published online January 9, 2012, in the American Journal of Pathology.

Related Links:

Albert Einstein College of Medicine
Montefiore Medical Center


KARL HECHT GMBH & CO KG
CELLAVISION AB
MEDLAB Asia

Channels

Microbiology

view channel
Image: The Xpert MTB/RIF cartridge-based, fully automated molecular diagnostic test for tuberculosis (Photo courtesy of Cepheid).

Test Helps Physicians Remove Suspected TB Patients from Isolation

Tuberculosis (TB) is caused by the Mycobacterium tuberculosis complex (MTB-complex) and usually attacks the lungs and many people carry the MTB-complex bacteria without ever developing active disease.... Read more

Lab Tech.

view channel
Image:  The Flame – a miniature spectrometer for medical diagnostics, biotechnology, and life sciences, that brings flexible optical sensing power to laboratory and point-of-care instrument integration (Photo courtesy of Ocean Optics).

Next Generation Miniature Spectrometer Brings Flexibility to Diagnostics and Biotechnology

The mini spectrometer combines decades of pioneering miniature spectrometer design expertise with leading techniques, adding flexible optical sensing power to laboratory and point-of-care instrument integration.... Read more

Industry News

view channel
Image: Under a new partnership for liquid handling measurement automation, Artel will provide STRATEC’s innovative “Tholos” technology, which measures liquid and solid contents of 96- and 384-well microplates, under the name Artel “SDS” - Sample Detection System (Photo courtesy of Artel).

Artel Expands Portfolio with STRATEC Partnership for Automation Technology

Artel (Westbrook, Maine, USA), a leader in laboratory liquid handling measurement systems, and STRATEC Biomedical AG (Birkenfeld, Germany), a leader in automated systems for clinical diagnostics and biotechnology,... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
08 Mar 2015 - 12 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.